The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
Abstract Background There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer’s disease (AD) treatment trials. We reported previously a composite cognitive test score sensitive to tracking preclinical AD decline up to 5 years...
Main Authors: | Jessica B. Langbaum, Noel N. Ellison, Angelika Caputo, Ronald G. Thomas, Carolyn Langlois, Marie-Emmanuelle Riviere, Ana Graf, Cristina Lopez Lopez, Eric M. Reiman, Pierre N. Tariot, Suzanne B. Hendrix |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-020-00633-2 |
Similar Items
-
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
by: Philip S. Insel, et al.
Published: (2017-05-01) -
Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention
by: Benjamin M. Doherty, et al.
Published: (2015-06-01) -
Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease
by: Cláudia Y. Santos, et al.
Published: (2018-01-01) -
Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials
by: Terry E. Goldberg, et al.
Published: (2015-03-01) -
Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer’s disease after a 27-month delay interval
by: Jessica Alber, et al.
Published: (2020-03-01)